307 completed, 76 terminated, 44 recruiting, 30 active not recruiting. 253 Phase 2, 211 Phase 1, 32 Not applicable, 31 Phase 3, 8 Phase 4.
Follow Waldenstrom Macroglobulinemia: new trials by email Literature Review of Waldenstrom Macroglobulinemia trials Research Report on Waldenstrom Macroglobulinemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases. teclistamab OR talquetamab OR elranatamab OR linvoseltamab, BTK inhibitors (ibrutinib and zanubrutinib) - Waldenstrom Macroglobulinaemia, Multiple Myeloma | Phase 4 | Not yet recruiting | Anne Louise Tølbøll Sørensen | 400 | 2027-03-01 | 2026-03-16 |
| Teclistamab In Waldenstrom's Macroglobulinemia Teclistamab - Waldenstrom's Macroglobulinemia | Phase 2 | Not yet recruiting | Massachusetts General Hospital | 24 | 2027-02-19 | 2026-09-01 |
| Evaluation of Iopofosine I 131 vs. R-CD in WM Patients Iopofosine I 131, Rituximab (active comparator), Cyclophosphamate - Waldenstrom Macroglobulinaemia, Waldenstrom Macroglobulinemia | Phase 3 | Not yet recruiting | Cellectar Biosciences, Inc. | 219 | 2026-12-01 | 2026-08-14 |
| Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER) Pirtobrutinib, Mosunetuzumab - Waldenstrom Macroglobulinemia | Phase 2 | Not yet recruiting | University of Utah | 25 | 2026-11-01 | 2026-09-24 |
| Epcoritamab as Consolidative Therapy for Waldenstr(SqrRoot)(Delta)m Macroglobulinemia (WM) Treated With a Bruton Tyrosine Kinase Inhibitor (BTKi) epcoritamab - Waldenstrom Macroglobulinemia | Phase 2 | Not yet recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 24 | 2026-10-27 | 2026-10-22 |
| ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 38 | 2026-09-30 | 2026-10-05 |
| Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase Inhibitor Therapy Atrial Fibrillation (AF), Chronic Lymphocytic Leukemia | Not yet recruiting | Tina Baykaner | 500 | 2026-08-01 | 2026-07-17 | |
| A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies Lacutoclax+Rocbrutinib - Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Recruiting | Guangzhou Lupeng Pharmaceutical Company LTD. | 92 | 2026-07-14 | 2026-07-30 |
| Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors Connected home blood pressure monitoring with daily IPA supervision. - Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma ( FL) | Not applicable | Not yet recruiting | Centre Hospitalier de la côte Basque | 40 | 2026-07-01 | 2026-06-22 |
| A Study of ARC-02 in B-cell NHL ARC-02, Rituximab - B-cell Non Hodgkin Lymphoma | Phase 1 | Recruiting | Taiho Oncology, Inc. | 140 | 2026-06-22 | 2026-10-08 |
| Nemtabrutinib, Bortezomib, and Rituximab for WM NEBULA - Waldenstrom Macroglobulinemia | Phase 2 | Not yet recruiting | Seoul National University Hospital | 19 | 2026-06-01 | 2026-03-11 |
| A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) LY4152199 - IV - Lymphoma, Non-Hodgkin, B-cell Lymphoma | Phase 1 | Recruiting | Eli Lilly and Company | 215 | 2026-05-28 | 2026-10-08 |
| Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy Cosibelimab, Prednisone, Sirolimus - Cutaneous Squamous Cell Carcinoma, Skin Cancer | Phase 4 | Recruiting | Dana-Farber Cancer Institute | 80 | 2026-04-23 | 2026-08-11 |
| Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma MDX2003 - Lymphoma, Waldenström Macroglobulinemia (WM) | Phase 1 / Phase 2 | Recruiting | ModeX Therapeutics, An OPKO Health Company | 180 | 2026-04-13 | 2026-05-04 |
| Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) Venetoclax - Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma | Phase 2 | Active not recruiting | AbbVie | 14 | 2026-03-17 | 2026-09-09 |
| A Study of APG-3288 in Relapsed/Refractory Blood Cancers APG-3288 - Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL | Phase 1 | Recruiting | Ascentage Pharma Group Inc. | 180 | 2026-03-10 | 2026-10-15 |
| A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Macroglobulinemia Zaunbrutinib, Bendamustine and Rituximab for induction therapy, Zanubrutinib mono therapy for maintenance treatment - Waldenström Macroglobulinemia (WM) | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 43 | 2025-12-30 | 2025-12-02 |
| Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated for Waldenström Macroglobulinemia zanubrutinib + BGB-11417 - Waldenstrom Macroglobulinemia | Phase 2 | Not yet recruiting | French Innovative Leukemia Organisation | 102 | 2025-12-01 | 2025-11-26 |
| A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia Pacritinib - Waldenström Macroglobulinemia, Lymphoplasmacytic Lymphoma | Phase 2 | Recruiting | Shayna Sarosiek, MD | 30 | 2025-11-21 | 2025-12-05 |
| A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) Pirtobrutinib, Venetoclax, Rituximab - Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 40 | 2025-11-11 | 2026-09-30 |
Showing 20 of 521. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (344) · Lymphoma, B-Cell, Marginal Zone (343) · Lymphoma, Follicular (332) · Lymphoma, Mantle-Cell (313) · Lymphoma, Non-Hodgkin (275) · Lymphoma, Large B-Cell, Diffuse (267) · Burkitt Lymphoma (226) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (220) · Lymphoma, Large-Cell, Immunoblastic (200) · Lymphoma (197) · Hodgkin Disease (184) · Multiple Myeloma (161) · Lymphoma, Large-Cell, Anaplastic (149) · Lymphoma, T-Cell, Cutaneous (149)
Hemic and Lymphatic Diseases (521) · Cardiovascular Diseases (520) · Hemorrhagic Disorders (520) · Lymphatic Diseases (520) · Neoplasms by Histologic Type (520) · Vascular Diseases (520) · Blood Protein Disorders (519) · Hemostatic Disorders (519) · Immune System Diseases (519) · Immunoproliferative Disorders (519) · Paraproteinemias (517) · Hematologic Diseases (515) · Lymphoproliferative Disorders (490) · Neoplasms (487) · Neoplasms, Plasma Cell (437)
Rituximab (101) · Cyclophosphamide (63) · fludarabine phosphate (55) · Peripheral Blood Stem Cell Transplantation (52) · Mycophenolic Acid (34) · Bortezomib (33) · Whole-Body Irradiation (33) · ibrutinib (29) · Dexamethasone (28) · Tacrolimus (26) · Cyclosporine (25) · Busulfan (23) · Etoposide (22) · Filgrastim (20) · Melphalan (20)
National Cancer Institute (NCI) (51) · Fred Hutchinson Cancer Center (36) · Dana-Farber Cancer Institute (26) · Mayo Clinic (18) · Memorial Sloan Kettering Cancer Center (13) · Roswell Park Cancer Institute (11) · City of Hope Medical Center (10) · Case Comprehensive Cancer Center (9) · Jonsson Comprehensive Cancer Center (9) · M.D. Anderson Cancer Center (9) · Barbara Ann Karmanos Cancer Institute (8) · SWOG Cancer Research Network (8) · BeiGene (7) · Institute of Hematology & Blood Diseases Hospital, China (7) · Alliance for Clinical Trials in Oncology (6)
United States (419) · France (40) · Italy (37) · Germany (31) · United Kingdom (31) · Canada (28) · Spain (23) · China (21) · Australia (20) · Greece (15) · Poland (15) · South Korea (15) · Israel (11) · Japan (9) · Switzerland (9)
Brenda Sandmaier (10) · Ajay Gopal (7) · David Maloney (6) · Irene Ghobrial, MD (6) · Christos E. Emmanouilides, MD (5) · Philip L. McCarthy, MD (4) · Robert O. Dillman, MD, FACP (4) · Steven P. Treon, MD, MA, PhD (4) · Thomas E. Witzig, MD (4) · Andrew Branagan, MD, PhD (3) · Barry R. Meisenberg, MD (3) · Christian Buske, MD (3)
PMID 32499241, PMID 34398557, PMID 34515338, PMID 40674744, PMID 23065509, PMID 23233721, PMID 36375120, PMID 38502198, PMID 10552943, PMID 10764422, PMID 12663715, PMID 12738671, PMID 14508361, PMID 15370249, PMID 15459300, PMID 15466934, PMID 15493038, PMID 16061911, PMID 16520464, PMID 16710026, PMID 16896003, PMID 17020988, PMID 17312328, PMID 17353550, PMID 17397698, PMID 17943599, PMID 18327587, PMID 18418404, PMID 18463792, PMID 18645482, PMID 18648813, PMID 18698002, PMID 18713945, PMID 19015393, PMID 19118065, PMID 19170225, PMID 19238148, PMID 19506160, PMID 19751237, PMID 19826119, PMID 19841031, PMID 19900571, PMID 1994541, PMID 20103671, PMID 20142586, PMID 20142598, PMID 20166206, PMID 20229590, PMID 20595516, PMID 20837940
P30CA015704 (24), P30CA015083 (12), P01CA018029 (9), U10CA032102 (9), P01CA078902 (7), P30CA022453 (7), P30CA033572 (6), P30CA072720 (6), U01CA076576 (6), 2023 (5), P30CA006973 (5), P30CA016058 (5), P30CA043703 (5), U01CA062487 (5), U01CA062491 (5)